<?xml version="1.0" encoding="ISO-8859-1"?>
<!DOCTYPE ichicsr SYSTEM "http://www.accessdata.fda.gov/xml/icsr-xml-v2.1.dtd">
<ichicsr lang="en">
	<ichicsrmessageheader>
		<messagetype>ichicsr</messagetype>
		<messageformatversion>2.1</messageformatversion>
		<messageformatrelease>2.0</messageformatrelease>
		<messagenumb>4053108_286</messagenumb>
		<messagesenderidentifier>NovartisPH</messagesenderidentifier>
		<messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
		<messagedateformat>204</messagedateformat>
		<messagedate>20121211133617</messagedate>
	</ichicsrmessageheader>
	<safetyreport>
		<safetyreportversion>4</safetyreportversion>
		<safetyreportid>PHHY2012DE004006</safetyreportid>
		<primarysourcecountry>DE</primarysourcecountry>
		<occurcountry>DE</occurcountry>
		<transmissiondateformat>102</transmissiondateformat>
		<transmissiondate>20121211</transmissiondate>
		<reporttype>1</reporttype>
		<serious>1</serious>
		<seriousnessdeath>2</seriousnessdeath>
		<seriousnesslifethreatening>2</seriousnesslifethreatening>
		<seriousnesshospitalization>1</seriousnesshospitalization>
		<seriousnessdisabling>2</seriousnessdisabling>
		<seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
		<seriousnessother>2</seriousnessother>
		<receivedateformat>102</receivedateformat>
		<receivedate>20120105</receivedate>
		<receiptdateformat>102</receiptdateformat>
		<receiptdate>20121203</receiptdate>
		<additionaldocument>2</additionaldocument>
		<fulfillexpeditecriteria>1</fulfillexpeditecriteria>
		<companynumb>PHHY2012DE004006</companynumb>
		<medicallyconfirm>1</medicallyconfirm>
		<primarysource>
			<reporterfamilyname>PRIVACY</reporterfamilyname>
			<reportercountry>DE</reportercountry>
			<qualification>3</qualification>
		</primarysource>
		<primarysource>
			<reporterfamilyname>PRIVACY</reporterfamilyname>
			<reportercountry>DE</reportercountry>
			<qualification>5</qualification>
		</primarysource>
		<sender>
			<sendertype>1</sendertype>
			<senderorganization>NOVARTIS PHARMACEUTICAL CORPORATION</senderorganization>
			<senderdepartment>Clinical Safety and Epidemiology</senderdepartment>
			<senderfamilyname>Clinical Safety and Epidemiology</senderfamilyname>
			<senderstreetaddress>Novartis Pharmaceuticals Corp. Bldg 419, One Health Plaza</senderstreetaddress>
			<sendercity>East Hanover</sendercity>
			<senderstate>NJ</senderstate>
			<senderpostcode>07936</senderpostcode>
			<sendercountrycode>US</sendercountrycode>
			<sendertel>+1800378</sendertel>
			<sendertelextension>8567</sendertelextension>
			<sendertelcountrycode>US</sendertelcountrycode>
			<senderfax>+1973781</senderfax>
			<senderfaxextension>8001</senderfaxextension>
			<senderfaxcountrycode>US</senderfaxcountrycode>
			<senderemailaddress>gdss.configuration@pharma.novartis.com</senderemailaddress>
		</sender>
		<receiver>
			<receivertype>2</receivertype>
			<receiverorganization>ZZFDA</receiverorganization>
			<receiverdepartment>FDA</receiverdepartment>
			<receivertitle>Mr</receivertitle>
			<receivergivename>William</receivergivename>
			<receiverfamilyname>Taylor</receiverfamilyname>
			<receiverstreetaddress>5600 Fishers Lane Room 16B-45</receiverstreetaddress>
			<receivercity>Rockville</receivercity>
			<receiverstate>MD</receiverstate>
			<receiverpostcode>20857</receiverpostcode>
			<receivercountrycode>US</receivercountrycode>
			<receivertel>+1301827</receivertel>
			<receivertelextension>0964</receivertelextension>
			<receivertelcountrycode>US</receivertelcountrycode>
			<receiverfax>+1301594</receiverfax>
			<receiverfaxextension>0829</receiverfaxextension>
			<receiverfaxcountrycode>US</receiverfaxcountrycode>
			<receiveremailaddress>.</receiveremailaddress>
		</receiver>
		<patient>
			<patientinitial>--</patientinitial>
			<patientonsetage>55</patientonsetage>
			<patientonsetageunit>801</patientonsetageunit>
			<patientsex>2</patientsex>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Injection site induration</patientepisodename>
				<patientmedicalcomment>Indurations present under treatment with Betaferon, either to a greater or lesser extent, the patien</patientmedicalcomment>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Arrhythmia</patientepisodename>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Blood pressure increased</patientepisodename>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Pain</patientepisodename>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Muscle spasms</patientepisodename>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Fluid retention</patientepisodename>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Blood pressure</patientepisodename>
			</medicalhistoryepisode>
			<patientpastdrugtherapy>
				<patientdrugname>BETAFERON</patientdrugname>
				<patientdrugstartdateformat>610</patientdrugstartdateformat>
				<patientdrugstartdate>200108</patientdrugstartdate>
				<patientdrugenddateformat>102</patientdrugenddateformat>
				<patientdrugenddate>20090904</patientdrugenddate>
			</patientpastdrugtherapy>
			<reaction>
				<primarysourcereaction>Diabetes mellitus type 2</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Type 2 diabetes mellitus</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Type 2 diabetes mellitus</reactionmeddrapt>
				<termhighlighted>3</termhighlighted>
				<reactionstartdateformat>610</reactionstartdateformat>
				<reactionstartdate>201201</reactionstartdate>
				<reactionoutcome>1</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>MS relapse</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Multiple sclerosis relapse</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Multiple sclerosis relapse</reactionmeddrapt>
				<termhighlighted>3</termhighlighted>
				<reactionoutcome>1</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Headache</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Headache</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Headache</reactionmeddrapt>
				<termhighlighted>3</termhighlighted>
				<reactionoutcome>1</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Fever</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Fever</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Pyrexia</reactionmeddrapt>
				<termhighlighted>3</termhighlighted>
				<reactionoutcome>1</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Chills</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Chills</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Chills</reactionmeddrapt>
				<termhighlighted>3</termhighlighted>
				<reactionoutcome>1</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Indurations after injection on abdomen/ indurations on the abdomen (partly encysted)</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Injection site induration</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Injection site induration</reactionmeddrapt>
				<termhighlighted>2</termhighlighted>
				<reactionoutcome>3</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Induration and reddening after injection on abdomen</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Injection site redness</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Injection site erythema</reactionmeddrapt>
				<termhighlighted>2</termhighlighted>
				<reactionoutcome>3</reactionoutcome>
			</reaction>
			<test>
				<testname>Nuclear magnetic resonance imaging</testname>
				<moreinformation>1</moreinformation>
			</test>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>EXTAVIA</medicinalproduct>
				<obtaindrugcountry>DE</obtaindrugcountry>
				<drugauthorizationnumb>BLA 125290</drugauthorizationnumb>
				<drugauthorizationcountry>DE</drugauthorizationcountry>
				<drugauthorizationholder>NOVARTIS SECTOR: PHARMA</drugauthorizationholder>
				<drugstructuredosagenumb>1</drugstructuredosagenumb>
				<drugstructuredosageunit>012</drugstructuredosageunit>
				<drugdosagetext>1 ml, QOD (every other day)</drugdosagetext>
				<drugdosageform>Solution For Injection</drugdosageform>
				<drugadministrationroute>058</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Multiple sclerosis</drugindication>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>20090904</drugstartdate>
				<actiondrug>4</actiondrug>
				<activesubstance>
					<activesubstancename>INTERFERON BETA-1B</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Chills</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Chills</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Headache</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Headache</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Injection site erythema</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Injection site erythema</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Injection site induration</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Injection site induration</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Multiple sclerosis relapse</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Multiple sclerosis relapse</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Pyrexia</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Pyrexia</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Type 2 diabetes mellitus</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Type 2 diabetes mellitus</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>VERAHEXAL</medicinalproduct>
				<obtaindrugcountry>DE</obtaindrugcountry>
				<drugauthorizationcountry>DE</drugauthorizationcountry>
				<drugstructuredosagenumb>.5</drugstructuredosagenumb>
				<drugstructuredosageunit>032</drugstructuredosageunit>
				<drugseparatedosagenumb>2</drugseparatedosagenumb>
				<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
				<drugintervaldosagedefinition>804</drugintervaldosagedefinition>
				<drugdosagetext>0.5 DF, BID (120 at 1/2-0-1/2-0 per day)</drugdosagetext>
				<drugadministrationroute>048</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Blood pressure</drugindication>
				<actiondrug>5</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>VERAPAMIL HYDROCHLORIDE</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>GABAPENTIN</medicinalproduct>
				<obtaindrugcountry>DE</obtaindrugcountry>
				<drugauthorizationcountry>DE</drugauthorizationcountry>
				<drugstructuredosagenumb>.5</drugstructuredosagenumb>
				<drugstructuredosageunit>032</drugstructuredosageunit>
				<drugseparatedosagenumb>1</drugseparatedosagenumb>
				<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
				<drugintervaldosagedefinition>804</drugintervaldosagedefinition>
				<drugdosagetext>0.5 DF, QD (600 at 0-0-0-1/2 per day)</drugdosagetext>
				<drugadministrationroute>048</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Pain</drugindication>
				<actiondrug>5</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>GABAPENTIN</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>MAGNESIUM VERLA</medicinalproduct>
				<obtaindrugcountry>DE</obtaindrugcountry>
				<drugauthorizationcountry>DE</drugauthorizationcountry>
				<drugstructuredosagenumb>2</drugstructuredosagenumb>
				<drugstructuredosageunit>032</drugstructuredosageunit>
				<drugseparatedosagenumb>1</drugseparatedosagenumb>
				<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
				<drugintervaldosagedefinition>804</drugintervaldosagedefinition>
				<drugdosagetext>2 DF, QD (0-0-0-2 per day)</drugdosagetext>
				<drugadministrationroute>048</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Muscle spasms</drugindication>
				<actiondrug>5</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>MAGNESIUM CITRATE, MAGNESIUM GLUTAMATE, MAGNESIUM NICOTINATE</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>TORASEMIDE</medicinalproduct>
				<obtaindrugcountry>DE</obtaindrugcountry>
				<drugauthorizationcountry>DE</drugauthorizationcountry>
				<drugstructuredosagenumb>1</drugstructuredosagenumb>
				<drugstructuredosageunit>032</drugstructuredosageunit>
				<drugseparatedosagenumb>1</drugseparatedosagenumb>
				<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
				<drugintervaldosagedefinition>804</drugintervaldosagedefinition>
				<drugdosagetext>1 DF, QD (0-0-0-1 per day)</drugdosagetext>
				<drugadministrationroute>048</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Fluid retention</drugindication>
				<actiondrug>5</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>TORASEMIDE</activesubstancename>
				</activesubstance>
			</drug>
			<summary>
				<narrativeincludeclinical>Case number PHHY2012DE004006, is an initial spontaneous report received from a nurse via marketing program Extracare-G (DE-MS11-033EXTRACAR, vendor Dr. Scharm) on 05 Jan 2012 with follow up report received from a MS nurse on 06 Jun 2012. Follow up report received from a MS nurse on 29 Aug 2012 with follow up report received from a nurse via the EXTRACARE-G Service Center (DE-MS11-033EXTRACAR, vendor Dr. Scharm) on 24 Oct 2012 with follow-up report received from the MS nurse via the EXTRACARE-G Service Center (DE-MS11-033EXTRACAR, vendor Dr. Scharm) on 03 Dec 2012: This case refers to 55-year-old female patient (Patient ID: 1368). The patient injected Betaferon (interferon beta-1b) from Aug 2001 until switch to Extavia on 04 Sep 2009. The patient&#8217;s historical condition included indurations present under treatment with Betaferon, either to a greater or lesser extent, the patient injected predominantly into the abdomen, current condition cardiac arrhythmia and increased blood pressure. Concomitant medication included Verahexal 120 (verapamil hydrochloride) orally for blood pressure at a dose 1/2-0-1/2-0 per day, gabapentin 600 orally for pain at a dose 0-0-0-1/2 per day, Magnesium Verla (magnesium citrate, magnesium glutamate, magnesium nicotinate) orally for cramps in the legs at a dose 0-0-0-2 per day, vitamin complex orally at a dose 1-0-1-0 per day, Ibuhexal 400 mg (ibuprofen) orally for pain at a dose 0-0-0-1 per day, torasemide 20 mg orally for water retention at a dose 0-0-0-1 per day and all for a long time. The patient received Extavia 250 mcg/ml (interferon beta-1b) subcutaneous for the treatment of multiple sclerosis (MS) from 04 Sep 2009 at a dose of 1 ml every other day. Since long time (unspecified date), the patient was developed induration and reddening after injection on abdomen. On 25 Jan 2012, the patient was hospitalized for the events, fever, chills and headache. An MRT (magnetic resonance tomography) was performed and MS relapse was diagnosed which was treated with cortisone at a dose of 250 mg five times daily. Approximately Jan 2012 (unspecified date), diabetes mellitus type 2 was diagnosed, which was treated with metformin at a dose of 500 mg 2 times daily and metformin 1000 orally at 1/2-0-1/2-0 per day. The nurse informed that, the patient injected only in her abdomen area. The nurse reported that the patient was doing well again and that her diabetes was well controlled. The patient was exercising and all had worked well. The case was assessed as serious (hospitalization) for events MS relapse, fever, chills, headache and diabetes mellitus type 2 and non-serious for events indurations on the abdomen and reddening on the abdomen. The patient continued treatment with Extavia. The outcome of the events MS relapse, fever, chills, headache and diabetes mellitus type 2 was reported as complete recovery and for rest of the events it was condition unchanged. The causality was reported as suspected (certain) for the event induration after injection on abdomen, reddening on the abdomen and was not reported for all the other events.

Follow up report received from a MS nurse on 06 Jun 2012: Action taken with Extavia (ongoing), added treatment drugs (cortisone, metformin), added new events and their clinical course (fever, chills, headache, diabetes mellitus type 2, MS relapse) and updated outcome of the event induration after injection on abdomen (condition unchanged).

Follow up report received from a MS nurse on 29 Aug 2012: Nurse comment, event outcome (induration after injection on abdomen) and narrative was updated.

Follow up report received from a nurse via the EXTRACARE-G Service Center (DE-MS11-033EXTRACAR, vendor Dr. Scharm) on 24 Oct 2012: Updated outcome of the event, causality, action taken.

Follow-up report received from the MS nurse via the EXTRACARE-G Service Center (DE-MS11-033EXTRACAR, vendor Dr. Scharm) on 03 Dec 2012: Updated medical history, concomitant medications and narrative.</narrativeincludeclinical>
				<sendercomment>Review of reported data does not allow for a proper causality assessement for the event Type 2 diabetes mellitus.</sendercomment>
			</summary>
		</patient>
	</safetyreport>
</ichicsr>
